A 52-week study of gabapentin enacarbil in restless legs syndrome.

Objectives:This open-label, multicenter, 52-week extension study (NCT00333359) assessed the long-term safety and efficacy of gabapentin enacarbil in subjects with moderate-to-severe primary restless legs syndrome (RLS).Methods:Subjects had completed one of 4 randomized, double-blind parent studies (